When Medicines Meet Sunlight: The Rise of In Silico Phototoxicity Testing
One of the less obvious risks in drug development is not how a medicine works inside the body, but how it behaves in the real world, particularly when exposed to sunlight.
DMPK Unravelled: Breaking barriers in drug discovery
Time has always been the most serious concern in drug discovery, making it a race¾ not just to develop new treatments but also to deliver safe and effective medicines to patients more quickly.
Syngene partners with a client for Global Economy Decarbonization
Renewable energy sources are powerful energy alternatives that can tackle climate change challenges and fossil fuel depletion. The Performance & Specialty Materials (PSM) team at Syngene aimed to develop innovative materials for a customer advancing in clean energy solutions such as green hydrogen. This project contributes to global decarbonization efforts by addressing the challenges in […]
Enhancing Patient Compliance: Developing an ExtendedRelease Anti-Epileptic Drug
The current immediate-release (IR) tablet formulation for epilepsy1 , available in Europe, requires multiple doses due to the drug’s short half-life, making it inconvenient for patients. This case study explores the development of an extended-release (ER) formulation by Syngene’s Formulation Development team for an anti-epileptic drug, aimed at reducing the need for frequent dosing and […]
Syngene Enhances Bispecific Antibody Production
The GEM-DIMER™ platform is a proprietary technology developed by Hinge Bio. This technology allows the production of antibodies with enhanced multivalency and multispecificity, enabling the simultaneous targeting of multiple diseaseassociated antigens
Pharmaceutical Development of a Broad-Spectrum Antibacterial Candidate for Multidrug-Resistant Infections
The World Health Organization (WHO) has identified antimicrobial resistance (AMR) as one of the top ten global public health threats. Despite concerted global efforts, AMR infections caused 4.95 Mn deaths in 2019. A clinical-stage biopharmaceutical company has been working on AMR since 2016 in collaboration with Syngene.
(N-1) Perfusion Technology
In the dynamic world of biomanufacturing, the quest for improved efficiency and productivity continues to shape industry advancements. N-1 Perfusion Technology is a cutting edge innovation designed to enhance protein yield, particularly antibodies, which are critical for therapeutic applications.
In silico immunogenicity assessment for peptides with unnatural amino acids
The peptide therapeutics market comprises over 80 approved drugs, with many generics introduced upon patent expiration. The production of generics typically introduces additional peptide impurities. These impurities could trigger an undesired immune response, affecting safety and efficacy in patients.
Enhancing Prodrug Solubility with Syngene’s SynVent Platform
Prodrugs are medications that, once administered, are metabolized in the body to release the active ingredient. They help to improve a medication’s effectiveness and can in some cases avoid certain side effects or toxicities.
SynWeave™ : Redefining Cell Line Development for Next-Generation Biologics
The biopharmaceutical industry witnessed significant innovation, with many new recombinant protein therapeutics receiving FDA approval. However, these therapies are often costly, emphasizing the need for greater efficiency and productivity.